Respiratory Care of Big Data Communication to Prevent Respiratory Tract Infection Nursing Analysis of Patients with Heart Failure

Heart failure is the final stage of the development of heart disease, with a high mortality and disability rate. It poses a serious threat to human health and brings tremendous pressure to human society. Preventing respiratory infections in patients with heart failure is also the first priority of care. This article is aimed at studying the nursing analysis of respiratory tract care based on big data exchanges to prevent respiratory tract infections in patients with heart failure. This article uses benchmark and sample collection. Studies have shown that for Pseudomonas aeruginosa, its resistance to ampicillin, amoxicillin/clavulanic acid, cefazolin, cefuroxime, ceftriaxone, cefotaxime, and cefoxitin has reached more than 80%. It is also suitable for piperacillin, ticarcillin/clavulanic acid, piperacillin/tazobactam, cefepime, aztreonam, gentamicin, tobramycin, ciprofloxacin, and levofloxacin. The resistance rate of stars is within 10%-30%. These antibiotics are effective and can be used for clinical treatment. The drug resistance rates of ceftazidime, imipenem, meropenem, and amikacin were all lower than 10%, and the drug resistance rates of ceftazidime and imipenem were much lower than those reported in the 2016 literature. These antibiotics have become the most effective drugs for the treatment of Pseudomonas aeruginosa infections. Basically, good communication of respiratory care data is realized, thereby preventing respiratory care analysis of patients with heart failure.